Bio-Sourcing's Recent Achievements in Biomanufacturing
Bio-Sourcing, a pioneer in the biotherapeutic sector situated in Belgium, has successfully obtained significant funding aimed at transforming the accessibility of biomanufactured medicines. Not too long ago, Bio-Sourcing secured €2.5 million in grants along with €10 million in equity from the esteemed European Innovation Council (EIC) Accelerator.
Impact of EIC Accelerator Funding
This funding marks a pivotal moment for Bio-Sourcing. With these resources, the company is gearing up to push forward its ambitious endeavor of introducing the first biosimilar of adalimumab (Humira)—a widely used treatment for various autoimmune conditions—into clinical trials by 2027. This groundbreaking achievement is expected to result in considerable upfront payments and ongoing royalties, which will be reinvested into research and development, significantly boosting Bio-Sourcing's ability to launch more biosimilars into the market.
Dr. Bertrand Merot's Vision
Discussing these recent advancements, Dr. Bertrand Merot, the founder and CEO, shared his enthusiasm for the future. He remarked, "Our BioMilk platform represents a significant leap for the biopharmaceutical sector. The financial support from the EIC Accelerator underscores the transformative potential of our innovative method in tackling urgent global healthcare challenges. With this funding, we’re not just focused on making biotherapeutics more affordable; we’re also positioning Europe as a leader in the global biopharmaceutical landscape."
Bio-Sourcing’s Innovative BioMilk Platform
Central to Bio-Sourcing’s approach is its BioMilk platform, which specializes in producing biotherapeutics, especially monoclonal antibodies, using the milk from specially bred goats. This cutting-edge method taps into the natural abilities of goats to generate complex proteins in their milk. Remarkably, this approach is five times more cost-effective than traditional biomanufacturing methods and drastically reduces the environmental impact often linked to pharmaceutical production.
Strategic Significance of Domestic Production
The BioMilk platform's benefits reach far beyond just financial savings. By enabling local biosimilar production, Bio-Sourcing aims to play a crucial role in enhancing Europe’s self-reliance in biopharmaceutical manufacturing. This is especially vital in light of recent global health emergencies, which have highlighted the urgent need for increased self-sufficiency in critical medical supplies.
Expansion Plans for Bio-Sourcing
Alongside the acquisition of this funding, Bio-Sourcing has detailed plans for expansion. These plans include upgrading their facilities, increasing their goat breeding operations, and constructing an advanced industrial milk processing plant. Such developments will not only support the company's growth but will also enhance its production capabilities, resulting in higher output and efficiency.
About Bio-Sourcing
Bio-Sourcing stands at the cutting edge of biotechnology, having created an innovative and economically viable platform for producing a new wave of biotherapeutics. This encompasses monoclonal antibodies developed using advanced technologies like genome editing and nuclear transfer. With the demand for biotherapeutics on the rise, Bio-Sourcing's dedication to sustainable production practices positions it as a vital player in the future of healthcare.
Frequently Asked Questions
What is Bio-Sourcing known for?
Bio-Sourcing is well-known for its groundbreaking biomanufacturing techniques, particularly in the production of monoclonal antibodies through its distinct BioMilk platform.
What funding has Bio-Sourcing secured?
The company has received €2.5 million in grants and €10 million in equity from the European Innovation Council (EIC) Accelerator.
What will the funding support?
This funding will enable Bio-Sourcing to advance its first biosimilar of adalimumab into clinical trials and expand its production facilities.
What is the BioMilk platform?
The BioMilk platform facilitates the production of complex proteins in goat’s milk, making the process more affordable and environmentally friendly.
Why is local biosimilar production important?
Local biosimilar production strengthens Europe’s ability to be self-sufficient in critical pharmaceutical supplies, which has become especially apparent during global health crises.
